Notice of Allowance is for the 23rd US Patent to be Awarded to Aclarion

New Patent Allows Aclarion Exclusive Access to Enhanced Post-processing Techniques of Magnetic Resonance Spectroscopy (MRS) to Improve Data Quality

Aclarion’s Patent Portfolio Continues to Grow in Support of a Platform Technology That can be Leveraged for Potential Future MRS Product Expansions Into Breast, Prostate, and Brain

BROOMFIELD, CO - (NewMediaWire) - June 20, 2024 - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for the 23rd  US patent that will be issued to the Company.  The patent relates to novel post-processing techniques to improve the quality of the spectral data derived from non-invasive MRS exams.  This improved quality enables more accurate quantification of the chemical biomarkers used by the Nocican solution. Allowance of this patent protects Aclarion’s market leader position as the world’s only SaaS platform delivering advanced chemical biomarker data to help physicians non-invasively identify the source of chronic low back pain (cLBP).

“This patent marks yet another validation of Aclarion’s unique commitment to engage expert engineering talent to overcome many of the issues that have historically challenged MRS,” said Brent Ness, President and Chief Executive Officer at Aclarion.  “While these advancements are improvements to MRS science in general, we are especially excited by the continued expansion of our patent portfolio for our disruptive Nociscan platform to ultimately help doctors better locate, and potentially better treat, painful degenerated discs that are causing cLBP.”

MRS is an existing capability of leading magnetic resonance imaging (MRI) scanners which are commonly used today for medical imaging.  MRI creates images of the soft tissue structures of the body while MRS generates spectral data information on the levels of various chemical biomarkers within the soft tissues such as proteins, carbohydrates, acids, etc. However, conventional MRS post-processing approaches can be challenging and fall short of generating sufficient quality data for reliable chemical analysis.  Several of Aclarion’s patents relate to various novel inventions that address many of these challenges, resulting in more reliable, higher quality spectral data for more accurate chemical biomarker analysis, ensuring the accuracy and reliability of the Nociscan solution.

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.  For more information, please visit www.aclarion.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company's current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:

Kirin M. Smith

PCG Advisory, Inc.

646.823.8656

ksmith@pcgadvisory.com

Media Contacts:

Jodi Lamberti

SPRIG Consulting

612.812.7477

jodi@sprigconsulting.com